ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2617

Serum 14-3-3eta Protein Elevation in Osteoarthritis Suggests Misclassification or Concurrent Inflammatory Arthritis

Olga S. Zhukov1, Jonnielyn G. Rivera1, Rania W. Abolhosn1, Robert J. Lagier2, Charles M. Rowland3, Joanna M. Popov1, Kaleb Michaud4 and Stanley J. Naides1, 1Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, 2Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, 3Research Support, Quest Diagnostics Alameda, Alameda, CA, 4Rheumatology & Immunology, University of Nebraska Medical Center and National Data Bank, Omaha, NE

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, Diagnostic Tests, Osteoarthritis, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Tissue distribution of the chaperonin 14-3-3η (eta) is limited to synovial tissue and brain. Synovium releases proinflammatory 14-3-3η into synovial fluid and serum in rheumatoid arthritis (RA) patients and, to a lesser extent, erosive psoriatic arthritis (PsA) patients. Serum measurement aids RA diagnosis (sensitivity 64% in early RA and 77% in established RA) and prognosis, and may have utility in assessing disease activity.1,2  Differentiating RA or PsA from osteoarthritis (OA), or identifying inflammatory arthritis in the presence of co-existing OA can be difficult. The purpose of this study was to estimate the specificity of 14-3-3η among a cohort of subjects with physician-confirmed OA.

Methods: Participants in the U.S.-based Arthritis Internet Registry (AIR) were surveyed by questionnaire. Physician and/or medical records were queried. Serum samples from patients with physician-confirmed diagnoses of OA (n=169) were tested for C-reactive protein (CRP) and rheumatoid factor (RF) by nephelometry, cyclic citrullinated peptide antibody (CCP) by ELISA, and 14-3-3η by a proprietary laboratory-developed ELISA test.

Results:  Of 169 physician-diagnosed OA patients tested, 11 (6.5%; 95% CI 3.3% to 11.3%) were positive for 14-3-3η. However, for 1 of the 11, CRP was 0.3 mg/dL, (normal, <0.8 mg/dL), RF was 123 IU/ml (normal <14 IU/mL), CCP was >250 Units (normal, <20 Units), and 14-3-3η was 1.9 ng/mL (normal, <0.2 ng/mL); the subject was subsequently reclassified as RA. Another subject’s CRP, RF, and CCP were nomral, but 14-3-3η was 3.1 ng/mL; subsequently, the subject was diagnosed with PsA based on new onset dactylitis in 2 fingers, joint pain, and changes in fingernails, all in the absence of prior psoriasis. A third subject had previously been treated for RA with methotrexate and entanercept; CRP was 4.4 mg/dL, RF was >1,200 IU/mL, CCP was >250 Units, and 14-3-3η was >20 ng/mL. Excluding the 3 subjects with subsequent diagnoses of RA or PsA, 8 of 166 OA subjects were 14-3-3η positive, or 4.8% (95% CI 2.1% to 9.3%). The specificity in OA subjects for 14-3-3η as a marker of inflammatory arthritis was 95.2% (95% CI 90.7% to 97.9%).

Conclusion:   In the present study, the low frequency of 14-3-3η in a cohort of individuals with OA supports the high specificity of 14-3-3η observed for RA. Further, 14-3-3η may be used to help identify RA or PsA patients amongst those being followed for OA. 14-3-3η may be particularly useful in the primary care setting to screen OA patients for misclassification of RA or PsA as OA, or for concurrent inflammatory arthritis in the setting of OA. 

References:  1. Maksymowych, et al. J Rheum. 2014;41:2104-13; 2. Maksymowych, et al. Clin Exp Rheum. 2014;32(Suppl 85):S35-9.


Disclosure: O. S. Zhukov, Quest Diagnostics, 3; J. G. Rivera, Quest Diagnostics, 3; R. W. Abolhosn, Quest Diagnostics, 3; R. J. Lagier, Quest Diagnostics, 3; C. M. Rowland, Quest Diagnostics, 3; J. M. Popov, Quest Diagnostics, 3; K. Michaud, None; S. J. Naides, Quest Diagnostics, 3.

To cite this abstract in AMA style:

Zhukov OS, Rivera JG, Abolhosn RW, Lagier RJ, Rowland CM, Popov JM, Michaud K, Naides SJ. Serum 14-3-3eta Protein Elevation in Osteoarthritis Suggests Misclassification or Concurrent Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/serum-14-3-3eta-protein-elevation-in-osteoarthritis-suggests-misclassification-or-concurrent-inflammatory-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-14-3-3eta-protein-elevation-in-osteoarthritis-suggests-misclassification-or-concurrent-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology